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Influenza activity in Europe during the winter 2005-2006 started late January - early 
February 2006 and first occurred in the Netherlands, France, Greece and England. 
Subsequently, countries were affected in a random pattern across Europe and the 
period of influenza activity lasted till the end of April. In contrast to the winter seasons 
in the period 2001-2005, no west-east pattern was detected. In 12 out of 23 countries, the 
consultation rates for influenza-like illness or acute respiratory infection in the winter 
2005-2006 were similar or higher than in the winter 2004-2005, despite a dominance of 
influenza B viruses that normally cause milder disease than influenza A viruses. In the 
remaining 11 countries the consultation rates were lower to much lower than in the 
winter 2004-2005. The highest consultation rates were usually observed among children 
aged 0-14. The circulating influenza virus types and subtypes were distributed 
heterogeneously across Europe. Although the figures for total virus detections in Europe 
indicated a predominance of influenza B virus (58% of all virus detections), in many 
countries influenza B virus was predominant only early in the winter, whilst later there 
was a marked increase in influenza A virus detections. Among the countries where 
influenza A viruses were co-dominant with B viruses (9/29) or were predominant (4/29), 
the dominant influenza A subtype was H3 in seven countries and H1 in four countries. 
The vast majority of characterised influenza B viruses (90%) were similar to the 
B/Victoria/2/87 lineage of influenza B viruses that re-emerged in Europe in the winter 
2004-2005 but were not included in the vaccine for the influenza season 2005-2006. This 
might help to explain the dominance of influenza B viruses in many countries in Europe 
during the winter 2005-2006. The influenza A(H3) and A(H1) viruses were similar to the 
reference strains included in the 2005-2006 vaccine, A/California/7/2004 (H3N2) and 
A/New Caledonia/20/99 (H1N1), respectively. In conclusion, the 2005-2006 influenza 
epidemic in Europe was characterised by moderate clinical activity, a heterogeneous 
spread pattern across Europe, and a variable virus dominance by country, although an 
overall dominance of influenza B viruses that did not match the virus strain included in 
the vaccine was observed.  
  
Introduction  
Influenza has a considerable public health impact in Europe each winter. Although it is 
moderately contagious, it spreads rapidly by coughs and sneezes from people who are 
infected [1]. Influenza affects approximately 5-15% of the world’s population with upper 
respiratory tract infections during seasonal epidemics every year [2]. Seasonal epidemics are 
associated with substantial demands on healthcare resources and considerable costs due to 
increases in general practice consultation rates, clinical complications, hospitalisations, drug 
treatment and absence from work [3,4]. Although difficult to assess, it is estimated that 
between 250,000 and 500,000 people die from severe illness as a result of influenza virus 
infection every year [2].  
The European Influenza Surveillance Scheme (EISS, http://www.eiss.org) is a collaborative 
network of primary care physicians, epidemiologists and virologists that aims to contribute to 
a reduction in morbidity and mortality in Europe by active clinical and virological 
surveillance of influenza [5,6]. The participating national reference laboratories have 
functioned within EISS as the Community Network of Reference Laboratories for Human 
Influenza in Europe (CNRL) since 2003. They report virus detection and identification data to 
EISS and work on improving the virological surveillance [7,8]. EISS aims to cover all 
member states of the European Union (EU), as required by EU Decision 2119/98/EC on the 
establishment of dedicated surveillance networks for communicable diseases [9]. During the 
winter 2005-2006, the EISS network included all 25 EU countries, as well as Norway, 
Romania and Switzerland. A total of 38 national influenza reference laboratories participated 
in EISS.  
The identification of circulating viruses and the recognition of virological changes are major 
tasks for EISS in order to fulfil its early warning function [7]. There is a particular need to 
detect and monitor the emergence or re-emergence of viruses with pandemic potential and 
viruses that show a ‘mismatch’ with the vaccine strain components, and to monitor their 
clinical impact. During the winter period (from week 40 to week 20 of the following year) a 
Weekly Electronic Bulletin is published each Friday on the EISS website 
(http://www.EISS.org) and in the ECDC weekly Influenza News 
(http://www.ecdc.europa.eu/Health_topics/influenza/news_archive.html). This allows the 
network members, public health authorities and the general public to view influenza activity 
in all participating countries.  
This paper presents an analysis and interpretation of influenza surveillance data collected by 
European countries that were members of EISS during the winter 2005-2006. In addition, the 
article presents an analysis of the relative and temporal distribution of influenza A and B 
viruses in the winter season on the basis of data from the past 10 years, as the high percentage 
and early appearance of influenza B viruses during the winter 2005-2006 were considered 
unusual.  
Methods 
Population  
All 28 countries that were members of EISS during the winter 2005-2006 actively monitored 
influenza activity from about week 40 of 2005 to about week 20 of 2006 (Table 1 below). In 
this paper, England, Northern Ireland, Scotland and Wales are referred to as separate 
countries because they have their own surveillance systems. EISS is therefore considered to 
include 31 countries. The characteristics of the sentinel networks are summarised in Table 1 
of the article supplement (see: 
http://www.eiss.org/documents/eurosurveillance/eurosurveillance_supplement_2005_2006_w
inter.pdf). The median weekly population under clinical surveillance by the sentinel networks 
during the winter 2005-2006 varied from 0.4% to 100% of the total population of a country, 
representing a median number of 24.8 million inhabitants of Europe. In total, about 21,000 
general practitioners (GPs), paediatricians and other physicians participated in the sentinel 
surveillance during the winter 2005-2006. However, the weekly number of physicians that 
actually reported was often lower. In general, the age distribution of the population under 
surveillance was representative for the age distribution of the total population in a country. 
However, in some countries the population under surveillance was skewed towards the lower 
age groups (partly due to a high proportion of paediatricians) and/or higher age groups. 
Further information on the representativeness of the population under surveillance in EISS 
can be found for most countries in Aguilera et al. [10].  
 Clinical surveillance  
In each of the countries, except Finland, one or several networks of sentinel physicians 
reported consultation rates due to influenza-like illness (ILI) and/or acute respiratory infection 
(ARI) on a weekly basis (for case definitions see: 
http://www.eiss.org/html/case_definitions.html). Twenty-six countries reported ILI 
consultations per 100,000 population; Malta and Cyprus reported ILI per 100 consultations 
and France and Germany reported ARI consultations per 100,000 population. In some 
countries the doctors have patients’ lists, which can provide an exact population denominator. 
In other countries people have a free choice of doctors, which means that the population 
denominator has to be estimated.  
Virological surveillance  
A proportion of the sentinel physicians, in most cases representative of the surveillance 
network in a country, also collects nose and/or throat swabs for virological surveillance using 
a swabbing protocol that guarantees representative swabbing during the winter period (see 
Table 1 in the article supplement) [10]. Combining clinical and virological data in the same 
population allows the evaluation of clinical reports made by the sentinel physicians and 
provides virological data for a clearly defined population - the general population that lives in 
the area served by the participating physician [11]. In addition to specimens obtained from 
physicians in the sentinel surveillance systems, the laboratories also collect and report results 
on samples obtained from other sources (e.g. from hospitals and non-sentinel physicians). 
These data are called ‘non-sentinel’ and are collected in order to have a second measurement 
of influenza activity (which contributes to early warning as the entire population is not 
covered by the sentinel system) and in order to assess the representativeness of the virological 
data obtained from the sentinel physicians [11]. Based on the collection of virological data, 
the total population under surveillance by EISS, during the winter 2005-2006, was almost 
equal to 495 million inhabitants living in the area covered by EISS [12].  
The virological data includes mostly results from cell cultures followed by virus type and 
subtype identification and from rapid diagnostic enzyme-immunological or 
immunofluorescence tests identifying the virus type only. Many laboratories also use reverse 
transcription polymerase chain reaction (RT-PCR) routinely for detection, typing and 
subtyping. Almost 50% (15/31) of the countries reported antigenic characterisation data and 
almost 30% (9/31) of the countries reported genetic characterisation data of the virus isolates 
during the winter 2005-2006.  
In addition to the circulation of the seasonal human influenza viruses, EISS laboratories 
monitored the possible transmission of the highly pathogenic avian influenza virus A(H5N1) 
to humans in the countries covered by EISS.  
The timing of the circulation of influenza A and B viruses and their relative distribution in the 
winter seasons was analysed using 10-year EISS data (1996-2006).  
Indicators  
During the winter period, the weekly clinical and virological data were collected and analysed 
by the national centres and then processed into the EISS database the following week via the 
internet [13]. The clinical consultation rates, the indicators of influenza activity (the intensity 
of clinical activity and the geographical spread of influenza), as well as the dominant virus 
type/subtype circulating in the population were established on a weekly basis by the national 
co-ordinators based on agreed definitions (see Box below) that were published previously 
[8,14]. The dominant type/subtype for the whole winter season was estimated per country 
(Table 1 above) using the algorithm published previously [14].  
 Spatial analysis  
A spatial analysis of the timing of peak influenza activity across Europe was carried out using 
regression analysis of plots of the longitude and latitude of the centre of each country against 
the week of peak influenza activity of each country, as described previously [14].  
Statistics  
SPSS version 14.0 for Windows was used for statistical analyses. A P-value <0.05 was 
considered significant.  
Results 
The seasonal influenza epidemic started late in Europe, with consultation rates for ILI or ARI 
above levels seen outside the winter period first reported in the Netherlands (week 1/2006), 
France (week 4/2006), and England and Greece (week 5/2006) (Graphs 1 and 2 in article 
supplement). Only two countries reported a high intensity of clinical activity, Estonia in 
weeks 11-12/2006 and Lithuania in week 8/2006 (Table 1 above). Most countries (19 out of 
30) reported at maximum a medium intensity. However, 11 countries reported low or very 
low levels of intensity and/or consultation rates for ILI or ARI: Austria, Germany, Hungary, 
Italy, Poland, Portugal, Romania, Scotland, Slovenia, Sweden and Wales. Overall, in 12 out 
of 23 countries, the consultation rates for ILI or ARI in the 2005-2006 winter were similar or 
higher when compared with the 2004-2005 winter, whereas in the remaining 11 countries the 
rates were lower to much lower (Graph 2 in article supplement).  
The ILI and ARI consultation rates in Europe reached their peak as early as week 1/2006 in 
Scotland and as late as week 13/2006 in the Czech Republic, Malta, Romania and Slovakia, 
indicating that the influenza epidemic took at least 13 weeks to spread across Europe.  
In individual countries, the week of peak ILI/ARI consultation rates coincided roughly with 
the week of peak sentinel influenza virus detections. In the 25 countries with paired data that 
could be evaluated the median week of peak ILI/ARI consultation rates was 10 (range week 1 
– 13) and the median week of peak virus detections was 9 (range week 5 – 15) (Table 1 
above). In eight (32%) of the 25 countries, the week of peak consultation rates coincided 
exactly with the week of peak virus detections. Including the countries with a difference of 
one week between the two peaks, the peak rates coincided in 15 (60%) of the 25 countries.  
In countries reporting age specific data (N=21), the highest consultation rates during the 
influenza peak were observed among children in the 0-4 and 5-14 age groups, although 
consultation rates in Norway and Wales were also high in the 15-64 age group compared to 
those in the other age groups (Table 1 above).  
In contrast to the previous four winters (2001-2005), the spatial analysis revealed no west-east 
pattern in the timing of peak influenza activity across Europe during the 2005-2006 winter (R2 
= 0.032; P=0.491 for west-east and R2 = 0.002; P=0.872 for south-north).  
For Europe as a whole, the largest number of influenza virus positive specimens was detected 
in week 8/2006 (Figure 1). About 80% of all influenza A(H1) virus detections were from 
Belgium, England, France, Italy, Portugal and Spain. In addition, the only influenza A virus H 
subtype detected in Luxembourg was H1. Twelve countries reported laboratory results for 
detection of the A(H5N1) virus but none of the 112 specimens from suspected and (possibly) 
exposed humans analysed were positive for the A(H5N1) virus. For a detailed breakdown of 
the virological data for Europe as a whole and by country, by week and source (sentinel or 
non-sentinel) see Figure 2 below, as well as Graph 2 and Tables 2 and 3 in the article 
supplement.  
 
 The distribution of virus types and subtypes by country and source (sentinel or non-sentinel) 
was analysed to evaluate the hypothesis that influenza B and A(H1N1) viruses are more often 
detected in sentinel specimens than in non-sentinel specimens (Tables 4 and 5 in the article 
supplement). By country (N=21), the proportion of type B viruses among viruses from 
sentinel specimens compared to viruses from non-sentinel specimens was significantly higher 
(P<0.05; Pearson Chi-Square) in ten countries, significantly lower (P<0.05) in two countries 
and not significantly different in the remaining nine countries. In contrast, by country (N=14), 
the proportion of A(H1) viruses among the type A viruses from sentinel specimens compared 
to non-sentinel specimens was significantly (P<0.05) lower in five countries, significantly 
higher in Spain only (89% vs 78%; P=0.032), whilst it was not significantly different in the 
remaining eight countries.  
By dominant type and subtype, the circulating influenza viruses were distributed 
heterogeneously across Europe (Table 1 above). Although the figures for Europe as a whole 
indicated a predominance for influenza B virus (58% of all virus detections) (Figure 2), in 
many countries early in the winter influenza B virus was predominant whilst later in the 
winter there was a marked increase in influenza A virus detections (Graph 2 in the article 
supplement). Influenza B virus was the dominant virus in 16 countries. In the countries where 
influenza A viruses were co-dominant with B viruses (9/29) or were predominant (4/29), the 
dominant influenza A virus subtype was H3 in seven countries and H1 in four countries 
(Table 1 above).  
The circulation of influenza B virus in the winter 2005-2006 was exceptional compared with 
data from the last decade (Figure 3). The winter 2005-2006 was the only one in Europe in ten 
years in which influenza B viruses were dominant. Influenza B virus circulation was 
suppressed (<6% of all viruses) in the winters where there was a full-blown circulation of a 
new drift variant of the A(H3N2) virus, i.e. in the 1997-1998, 1999-2000 and 2003-2004 
winters. In the other six winters the proportion of B viruses among all viruses did not exceed 
36% (mean 27%; range 17-36%). In addition, the winter 2005-2006 was the only one in 
which, for Europe as a whole, influenza B viruses started to circulate and peaked earlier (3 
weeks) than influenza A viruses. Of the previous nine winters, in four, the influenza B viruses 
started to circulate and peaked later than influenza A viruses (mean 5 weeks; range 3-7 
weeks), in three, influenza A and B viruses started to circulate and peaked at the same time 
and in two, the timing could not be estimated as influenza B viruses were almost completely 
absent.  
 Of all 11,303 influenza virus detections, 3,128 have been antigenically and/or genetically 
characterised: 683 (28%) were A/New Caledonia/20/99 (H1N1)-like, 370 (12%) were 
A/California/7/2004 (H3N2)-like, 56 (2%) were A/Wisconsin/67/2005 (H3N2)-like (a drift 
variant of A/California/7/2004 included in the vaccine for the 2006-2007 winter), 1,816 
(58%) were B/Malaysia/2506/2004-like (B/Victoria/2/87-lineage) and 203 (6%) were 
B/Jiangsu/10/2003-like (B/Jiangsu/10/2003 is a B/Shanghai/361/2002-like virus from the 
B/Yamagata/16/88-lineage that was included in the vaccine for the 2005-2006 influenza 
season).  
Discussion 
In the winter 2005-2006, influenza activity in Europe started late in January 2006, whereas in 
the previous winter it began in late December 2004 [14]. The 2005-2006 winter was the first 
one since 1996 in which, for Europe as a whole, the number of influenza B virus detections 
was higher than the number of influenza A virus detections (Figure 2). However, on a country 
level, virus type and even H-subtype dominance were very heterogeneous across Europe 
(Table 1 above). Most of the circulating influenza B viruses (90%) were similar to the 
B/Victoria/2/87 lineage of influenza B viruses that re-emerged in Europe in the winter 2004-
2005 [14], but were not included in the vaccine for the influenza season 2005-2006. 
Remarkably, in a number of countries, a high number of influenza A(H1) viruses were 
detected compared to A(H3) viruses. Despite the predominant circulation of the B and A(H1) 
viruses, generally known to cause milder illness than A(H3) viruses [15], the peak of clinical 
influenza activity was similar or even higher in about half (12/23) of the countries, compared 
to the previous winter when A(H3) viruses were dominant [14] (Graph 2 in the article 
supplement).  
Previously, we reported that a pattern could be seen in the timing of peak influenza activity in 
countries across Europe, mainly being a west-east movement, sometimes accompanied by a 
south-north movement later on in the winter [14]. However, the winter 2005-2006 did not fit 
into this pattern, as influenza activity started to peak in countries located in different parts of 
Europe and, subsequently, spread randomly across the whole region (Graph 1 in the article 
supplement). Viboud et al. showed that in the USA severe influenza epidemics, dominated by 
A(H3N2), are more synchronous (i.e. spread more quickly from state to state) than the milder 
epidemics, generally caused by A(H1N1) and B viruses [16]. In addition, they showed that 
population size and strong long-range human movement connections between states seem to 
be important for synchrony and spatio-temporal spread of influenza. As the 2005-2006 winter 
in Europe was heterogeneous with regard to circulating virus types and subtypes by country 
and with regard to the location of countries were influenza activity initially started to increase, 
the observations of Viboud et al. might explain the absence of a pattern in the timing of peak 
influenza activity for countries across Europe in the 2005-2006 winter.  
In 10 out of 21 countries, the proportion of influenza B viruses was significantly higher 
among viruses detected in sentinel specimens compared to non-sentinel specimens. It can be 
explained by the fact that influenza B virus infections are mostly mild [15] and patients 
usually do not need hospital care. Although this assumption of the link between mild infection 
and low hospitalisation rate could be applied also in case of A(H1N1) infections, in only one 
out of 14 countries the proportion of A(H1) viruses was higher among type A viruses from 
sentinel specimens compared to non-sentinel specimens, whereas in 5 out of 14 countries, the 
proportion of A(H1) viruses was significantly lower among influenza A viruses detected in 
sentinel specimens compared to non-sentinel specimens. Hence, the severity of disease caused 
by the influenza B and A(H1N1) viruses is probably not the only factor that explains the 
differences between viruses detected in sentinel and non-sentinel specimens. Possibly, 
differences in the age distribution between and within the population under surveillance in the 
sentinel systems (Table 1 above in the article supplement) and patients consulting a physician 
in the non-sentinel systems, differences in the age distribution of the patients from whom a 
swab is taken between and within the sentinel and non-sentinel systems, in combination with 
the patients’ vaccination and infection histories, might provide further explanations. More 
systematic analysis of available data and of the various surveillance systems is needed to draw 
more definitive conclusions.  
The currently circulating influenza B viruses are antigenically and genetically divided into 
two distinct lineages represented by B/Yamagata/16/88 and B/Victoria/2/87 viruses, which 
have evolved to an extent that antibodies raised to viruses of one lineage offer reduced cross-
reactive protection against viruses of the other lineage [17,18]. The trivalent influenza vaccine 
contains, however, only one B virus component. Because most B viruses isolated in the world 
by February 2005 were of the B/Yamagata/16/88 lineage type, the WHO recommended the 
inclusion of the B/Shanghai/361/2002-like virus (B/Yamagata/16/88 lineage) in the vaccine 
for the Northern Hemisphere 2005-2006 influenza season, similarly to the vaccine for the 
previous season 2004-2005 [17]. In Europe, however, already in the winter 2004-2005 the 
proportion of influenza B virus detections was higher than in the winter 2003-2004 - 17% 
compared to <1% respectively. Of these viruses, 43% belonged to the B/Victoria/2/87 lineage 
in the winter 2004-2005 as compared to 35% in the winter 2003-2004 [14,19]. This increasing 
trend continued in the winter 2005-2006 when about 90% of the detected influenza B viruses 
belonged to the B/Victoria/2/87 lineage viruses. The emergence of B/Victoria/2/87 lineage 
viruses, which showed limited circulation in previous seasons, combined with the reduced 
cross immunity induced by B/Yamagata/16/88 lineage viruses and the mismatch with the 
vaccine may explain the dominance of influenza B viruses in the winter 2005-2006.  
The World Health Organization announced the composition of the influenza vaccine for the 
Northern Hemisphere 2006-2007 influenza season in February 2006 [20]. Based on the 
analysis of influenza viruses from all over the world up until February 2006, the WHO 
modified the composition of the 2006-2007 influenza vaccine compared to the 2005-2006 
vaccine by including a representative strain of the B/Victoria/2/87 lineage of influenza B 
viruses (B/Malaysia/2506/2004-like) and a more recent A(H3N2) strain 
[A/Wisconsin/67/2005 (H3N2)-like]. In Europe, the vaccine composition recommended by 
the European Agency for the Evaluation of Medicinal Products, which is based on the WHO 
recommendations, was adopted for the vaccination campaigns in winter 2006-2007 [21].  
The patterns observed when comparing the proportion of circulating influenza B viruses and 
the timing of onset of circulation and peaking of influenza B viruses with influenza A viruses 
for Europe as a whole (Figure 3) are not necessarily the same for individual countries. This is 
because the data for Europe as a whole is cumulated per week and not compensated for the 
time it takes the epidemic to spread across Europe (at least 13 weeks for the winter 2005-
2006). The analysis of the timing pattern of circulation of influenza A and B viruses on a 
country level (not shown in this paper) demonstrates that in each winter there are exceptions 
to the pattern observed for Europe as a whole, as has also been observed for the 2005-2006 
winter (compare Figure 1 for Europe as a whole with Graph 2 in the article supplement for 
individual countries). The patterns observed for Europe as a whole should therefore not be 
overinterpreted, and for a thorough analysis of distribution patterns of virus types and 
subtypes across Europe a finer analysis (e.g. on the country level) is currently being carried 
out.  
During the winter 2005-2006, the A(H5N1) influenza virus which in Asia had caused 
epizootics and cases of transmission to humans with fatalities [22] appeared in Europe 
causing outbreaks in poultry and wild birds [23]. EISS received laboratory reports of 
A(H5N1) testing of human specimens, especially from EISS countries experiencing outbreaks 
among poultry and wild birds; all were negative. In Europe, human cases were only detected 
in Turkey [24]. However, this "near miss" situation in the area covered by EISS stressed the 
importance of pandemic preparedness activities, including laboratory capacity. Therefore, the 
EISS network made available to all participating laboratories up-to-date RT-PCR detection 
protocols, recent sequence information and A(H5) controls for RT-PCR detection [7, 8]. Most 
laboratories participating in EISS now have the possibility to rapidly detect the A(H5) virus 
by molecular techniques. A recent EISS external quality assessment (EQA), carried out in 
collaboration with Quality Control for Molecular Diagnostics (http://www.qcmd.org), aimed 
at evaluating the detection, typing and subtyping of influenza viruses including the H5 virus, 
showed that about 65% (21/32) of the responding EISS laboratories were indeed capable of 
detecting the H5 virus. However, the study indicated also need for improvement, especially 
with regard to the sensitivity of the tests being used. Real-time RT-PCR tests outperformed 
block RT-PCR tests and the commercially available RT-PCR kits of which some failed to 
detect the A(H5) virus completely.  
In conclusion, the 2005-2006 influenza epidemic in Europe was characterised by a late onset 
of influenza activity and a heterogeneous spread pattern across Europe. In addition, an 
uncommon overall dominance of influenza B viruses of the B/Victoria/2/87 lineage was 
observed, as well as an earlier onset of circulation and peaking of influenza B virus compared 
to influenza A virus, and a relatively high proportion of influenza A(H1) viruses in a number 
of countries.  
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